CAMBIUM BIO LIMITED - Announcements

Market Cap $4.533M Add to my watchlist

Healthcare Biotechnology

Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage... Cambium Bio Limited, formerly Regeneus Ltd, is an Australia-based clinical-stage regenerative medicine company focusing on the development of biologics for ophthalmology and tissue repair applications. Its technology, based on human platelet lysate, is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. Its lead product candidate, Elate Ocular, is being developed to address significant unmet medical needs in the treatment of dry eye disease. Elate Ocular is formulated from the processing of base human platelets sourced not from patients, but generally healthier younger eligible donors at U.S. blood collection centers. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications. It also manufactures and sells stem cell growth supplements, such as UltraGRO Advanced, UltraGRO Pure (xeno-free), and UltraGRO Pure GI (xeno-free, gamma irradiated).More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

CMB	RGS receives Innovation Grant		18/12/19	127.26KB	Share
CMB	Results of the Annual General Meeting		21/11/19	2.91MB	Share
CMB	CEO Presentation to 2019 Annual General Meeting	PRICE SENSITIVE	21/11/19	819.25KB	Share
CMB	Chairman's Address to Shareholders	PRICE SENSITIVE	21/11/19	66.33KB	Share
CMB	Cleansing Statement		20/11/19	92.12KB	Share
CMB	Appendix 3B		20/11/19	467.56KB	Share
CMB	Japanese Biotech Fund takes up all Rights Issue Shortfall	PRICE SENSITIVE	19/11/19	135.62KB	Share
CMB	Response to ASX Appendix 4C Query	PRICE SENSITIVE	31/10/19	1005.4KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	31/10/19	297.16KB	Share
CMB	Appendix 4G and Corporate Governance Statement		30/10/19	314.33KB	Share
CMB	Annual Report 2019		30/10/19	1.15MB	Share
CMB	Notice of Annual General Meeting / Proxy Form		18/10/19	402.49KB	Share
CMB	Regeneus receives A$1.5 million in R&D Tax Incentives	PRICE SENSITIVE	15/10/19	99.45KB	Share
CMB	Change of Registered Office and Principal Place of Business		15/10/19	87.65KB	Share
CMB	Financial Report - Year Ended 30 June 2019		26/09/19	686.48KB	Share
CMB	Change of interests of substantial holder - Graham Vesey		11/09/19	201.32KB	Share
CMB	Notice of initial substantial holder - Leo Lee		11/09/19	130.24KB	Share
CMB	Date of AGM		10/09/19	90.08KB	Share
CMB	Appendix 3Y - Glen Richards		03/09/19	220.42KB	Share
CMB	Appendix 3Y - Leo Lee		03/09/19	216.52KB	Share
CMB	Appendix 3Y - Barry Sechos		03/09/19	221.4KB	Share
CMB	Appendix 3B		03/09/19	446.85KB	Share
CMB	Clarification to Announcement		30/08/19	109.2KB	Share
CMB	Rights Issue Shortfall Notice		30/08/19	63.57KB	Share
CMB	Appendix 4E	PRICE SENSITIVE	30/08/19	306.59KB	Share
CMB	Confirmation of Despatch of Offer Booklet		13/08/19	1.42MB	Share
CMB	Restructuring results in 50% reduction in operating costs	PRICE SENSITIVE	13/08/19	129.96KB	Share
CMB	Placement Appendix 3B and Cleansing Statement		07/08/19	540.14KB	Share
CMB	Updated Investor Presentation	PRICE SENSITIVE	07/08/19	612.85KB	Share
CMB	Letter to Shareholders - Non Renounceable Rights Issue		02/08/19	1.21MB	Share
CMB	Letter to Option holders		01/08/19	255.25KB	Share
CMB	Cleansing Notice		01/08/19	346.34KB	Share
CMB	Appendix 3B		01/08/19	456.04KB	Share
CMB	Offer Booklet	PRICE SENSITIVE	01/08/19	1.31MB	Share
CMB	Investor Presentation	PRICE SENSITIVE	01/08/19	624.27KB	Share
CMB	Successful Private Placement	PRICE SENSITIVE	01/08/19	125.64KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	31/07/19	224.56KB	Share
CMB	Trading Halt	PRICE SENSITIVE	30/07/19	378.14KB	Share
CMB	Positive results for Progenza in treating neuropathic pain	PRICE SENSITIVE	23/07/19	143.49KB	Share
CMB	New Strategy To Deliver Therapies For Global Pain Market		22/07/19	142.4KB	Share
CMB	Appendix 3X - Initial Director's Interest Notice		02/05/19	199.02KB	Share
CMB	Appendix 3Z - Final Director's Interest Notice		02/05/19	201.75KB	Share
CMB	Regeneus Appoints International Directors for Global Growth		29/04/19	90.47KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	11/04/19	438.84KB	Share
CMB	Appendix 4D and Half-Year Report	PRICE SENSITIVE	28/02/19	1.34MB	Share
CMB	Directors Provide $2.5M Loan to Extend Funding Runway	PRICE SENSITIVE	28/02/19	65KB	Share
CMB	Response to ASX Appendix 4C Query Letter	PRICE SENSITIVE	22/02/19	657.35KB	Share
CMB	Material Terms of Contract for Chief Executive Officer		01/02/19	36.49KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	30/01/19	239.42KB	Share
CMB	New CEO Appointed to Accelerate Global Growth	PRICE SENSITIVE	23/01/19	69.59KB	Share
CMB	Chinese patent granted for biomarkers for stem cell therapy	PRICE SENSITIVE	03/12/18	77.36KB	Share
CMB	Results of Annual General Meeting		22/11/18	404.1KB	Share
CMB	CEO Presentation to 2018 Annual General Meeting		22/11/18	1.64MB	Share
CMB	Chairman's Address to Shareholders		22/11/18	59.94KB	Share
CMB	Presentation for AusBiotech 2018		31/10/18	1.07MB	Share
CMB	Re-Released - Appendix 4C - Quarterly	PRICE SENSITIVE	24/10/18	231.27KB	Share
CMB	Appendix 4C - Quarterly		24/10/18	231.27KB	Share
CMB	Notice of Annual General Meeting / Proxy Form		19/10/18	852.43KB	Share
CMB	Progenza patent to grant in Europe	PRICE SENSITIVE	18/10/18	95.2KB	Share
CMB	Appendix 3Y Change of Director's Interest Notice		19/09/18	294.58KB	Share
CMB	Date of AGM		18/09/18	370.91KB	Share
CMB	Regeneus receives R&D tax incentive refund of $2.4m	PRICE SENSITIVE	06/09/18	103.36KB	Share
CMB	FY18 Results and Business Update		30/08/18	148.48KB	Share
CMB	FY18 Results and Business Update Presentation		30/08/18	1.59MB	Share
CMB	Appendix 4G and Corporate Governance Statement		30/08/18	319.69KB	Share
CMB	Annual Report 2018		30/08/18	1.95MB	Share
CMB	Appendix 4E	PRICE SENSITIVE	30/08/18	880.49KB	Share
CMB	Positive clinical trial results for cancer vaccine	PRICE SENSITIVE	30/07/18	125.95KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	25/07/18	224.84KB	Share
CMB	Response to ASX Price Query	PRICE SENSITIVE	23/07/18	985.56KB	Share
CMB	US Patent Office to allow key patent for Progenza	PRICE SENSITIVE	10/07/18	104.26KB	Share
CMB	Update on licensing Progenza in Japan	PRICE SENSITIVE	03/07/18	99.81KB	Share
CMB	Grant of ASX Waiver	PRICE SENSITIVE	28/06/18	166.21KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	26/04/18	3.27MB	Share
CMB	Appendix 3Y Change of Director's Interest Notice		20/04/18	226.04KB	Share
CMB	Positive trial results of Progenza for knee OA published		07/03/18	1.5MB	Share
CMB	Half-Year Results Presentation		20/02/18	682.6KB	Share
CMB	Half-Year Results Announcement		20/02/18	117.2KB	Share
CMB	Appendix 4D and Half-Year Report	PRICE SENSITIVE	20/02/18	1.04MB	Share
CMB	European Medicines Agency grants Progenza ATMP status	PRICE SENSITIVE	14/02/18	106.87KB	Share
CMB	Japanese Patent Office to grant patent for cancer vaccine	PRICE SENSITIVE	12/02/18	109.53KB	Share
CMB	Regeneus Announces Successful Results in Acne Study	PRICE SENSITIVE	06/02/18	138.41KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	25/01/18	3.3MB	Share
CMB	Regeneus appoints Japan-based non-executive director		11/12/17	796.11KB	Share
CMB	Results of Annual General Meeting		02/11/17	843.63KB	Share
CMB	CEO Presentation to 2017 Annual General Meeting	PRICE SENSITIVE	02/11/17	4.5MB	Share
CMB	Chairman's Address to Shareholders		02/11/17	208.22KB	Share
CMB	Presentation on Japan First Strategy at Ord Minnett		01/11/17	3.72MB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	24/10/17	1.14MB	Share
CMB	Notice of Annual General Meeting / Proxy Form		28/09/17	477.3KB	Share
CMB	Sygenus shows longer lasting effect on pain than morphine	PRICE SENSITIVE	26/09/17	256.91KB	Share
CMB	Date of AGM		06/09/17	370.74KB	Share
CMB	Regeneus receives R&D tax incentive refund of $2.6m	PRICE SENSITIVE	29/08/17	181KB	Share
CMB	Appendix 4E Revised	PRICE SENSITIVE	22/08/17	904.01KB	Share
CMB	FY17 Results Presentation		22/08/17	5.12MB	Share
CMB	FY17 Results Announcement		22/08/17	200.13KB	Share
CMB	Appendix 4G and Corporate Governance Statement		22/08/17	8.99MB	Share
CMB	Annual Report 2017		22/08/17	11.55MB	Share
CMB	Appendix 4E	PRICE SENSITIVE	22/08/17	906.63KB	Share
CMB	Appendix 4C - Quarterly	PRICE SENSITIVE	26/07/17	1.44MB	Share

CMB RGS receives Innovation Grant
18/12/19		127.26KB	Share
CMB Results of the Annual General Meeting
21/11/19		2.91MB	Share
CMB CEO Presentation to 2019 Annual General Meeting
21/11/19	PRICE SENSITIVE	819.25KB	Share
CMB Chairman's Address to Shareholders
21/11/19	PRICE SENSITIVE	66.33KB	Share
CMB Cleansing Statement
20/11/19		92.12KB	Share
CMB Appendix 3B
20/11/19		467.56KB	Share
CMB Japanese Biotech Fund takes up all Rights Issue Shortfall
19/11/19	PRICE SENSITIVE	135.62KB	Share
CMB Response to ASX Appendix 4C Query
31/10/19	PRICE SENSITIVE	1005.4KB	Share
CMB Appendix 4C - Quarterly
31/10/19	PRICE SENSITIVE	297.16KB	Share
CMB Appendix 4G and Corporate Governance Statement
30/10/19		314.33KB	Share
CMB Annual Report 2019
30/10/19		1.15MB	Share
CMB Notice of Annual General Meeting / Proxy Form
18/10/19		402.49KB	Share
CMB Regeneus receives A$1.5 million in R&D Tax Incentives
15/10/19	PRICE SENSITIVE	99.45KB	Share
CMB Change of Registered Office and Principal Place of Business
15/10/19		87.65KB	Share
CMB Financial Report - Year Ended 30 June 2019
26/09/19		686.48KB	Share
CMB Change of interests of substantial holder - Graham Vesey
11/09/19		201.32KB	Share
CMB Notice of initial substantial holder - Leo Lee
11/09/19		130.24KB	Share
CMB Date of AGM
10/09/19		90.08KB	Share
CMB Appendix 3Y - Glen Richards
03/09/19		220.42KB	Share
CMB Appendix 3Y - Leo Lee
03/09/19		216.52KB	Share
CMB Appendix 3Y - Barry Sechos
03/09/19		221.4KB	Share
CMB Appendix 3B
03/09/19		446.85KB	Share
CMB Clarification to Announcement
30/08/19		109.2KB	Share
CMB Rights Issue Shortfall Notice
30/08/19		63.57KB	Share
CMB Appendix 4E
30/08/19	PRICE SENSITIVE	306.59KB	Share
CMB Confirmation of Despatch of Offer Booklet
13/08/19		1.42MB	Share
CMB Restructuring results in 50% reduction in operating costs
13/08/19	PRICE SENSITIVE	129.96KB	Share
CMB Placement Appendix 3B and Cleansing Statement
07/08/19		540.14KB	Share
CMB Updated Investor Presentation
07/08/19	PRICE SENSITIVE	612.85KB	Share
CMB Letter to Shareholders - Non Renounceable Rights Issue
02/08/19		1.21MB	Share
CMB Letter to Option holders
01/08/19		255.25KB	Share
CMB Cleansing Notice
01/08/19		346.34KB	Share
CMB Appendix 3B
01/08/19		456.04KB	Share
CMB Offer Booklet
01/08/19	PRICE SENSITIVE	1.31MB	Share
CMB Investor Presentation
01/08/19	PRICE SENSITIVE	624.27KB	Share
CMB Successful Private Placement
01/08/19	PRICE SENSITIVE	125.64KB	Share
CMB Appendix 4C - Quarterly
31/07/19	PRICE SENSITIVE	224.56KB	Share
CMB Trading Halt
30/07/19	PRICE SENSITIVE	378.14KB	Share
CMB Positive results for Progenza in treating neuropathic pain
23/07/19	PRICE SENSITIVE	143.49KB	Share
CMB New Strategy To Deliver Therapies For Global Pain Market
22/07/19		142.4KB	Share
CMB Appendix 3X - Initial Director's Interest Notice
02/05/19		199.02KB	Share
CMB Appendix 3Z - Final Director's Interest Notice
02/05/19		201.75KB	Share
CMB Regeneus Appoints International Directors for Global Growth
29/04/19		90.47KB	Share
CMB Appendix 4C - Quarterly
11/04/19	PRICE SENSITIVE	438.84KB	Share
CMB Appendix 4D and Half-Year Report
28/02/19	PRICE SENSITIVE	1.34MB	Share
CMB Directors Provide $2.5M Loan to Extend Funding Runway
28/02/19	PRICE SENSITIVE	65KB	Share
CMB Response to ASX Appendix 4C Query Letter
22/02/19	PRICE SENSITIVE	657.35KB	Share
CMB Material Terms of Contract for Chief Executive Officer
01/02/19		36.49KB	Share
CMB Appendix 4C - Quarterly
30/01/19	PRICE SENSITIVE	239.42KB	Share
CMB New CEO Appointed to Accelerate Global Growth
23/01/19	PRICE SENSITIVE	69.59KB	Share
CMB Chinese patent granted for biomarkers for stem cell therapy
03/12/18	PRICE SENSITIVE	77.36KB	Share
CMB Results of Annual General Meeting
22/11/18		404.1KB	Share
CMB CEO Presentation to 2018 Annual General Meeting
22/11/18		1.64MB	Share
CMB Chairman's Address to Shareholders
22/11/18		59.94KB	Share
CMB Presentation for AusBiotech 2018
31/10/18		1.07MB	Share
CMB Re-Released - Appendix 4C - Quarterly
24/10/18	PRICE SENSITIVE	231.27KB	Share
CMB Appendix 4C - Quarterly
24/10/18		231.27KB	Share
CMB Notice of Annual General Meeting / Proxy Form
19/10/18		852.43KB	Share
CMB Progenza patent to grant in Europe
18/10/18	PRICE SENSITIVE	95.2KB	Share
CMB Appendix 3Y Change of Director's Interest Notice
19/09/18		294.58KB	Share
CMB Date of AGM
18/09/18		370.91KB	Share
CMB Regeneus receives R&D tax incentive refund of $2.4m
06/09/18	PRICE SENSITIVE	103.36KB	Share
CMB FY18 Results and Business Update
30/08/18		148.48KB	Share
CMB FY18 Results and Business Update Presentation
30/08/18		1.59MB	Share
CMB Appendix 4G and Corporate Governance Statement
30/08/18		319.69KB	Share
CMB Annual Report 2018
30/08/18		1.95MB	Share
CMB Appendix 4E
30/08/18	PRICE SENSITIVE	880.49KB	Share
CMB Positive clinical trial results for cancer vaccine
30/07/18	PRICE SENSITIVE	125.95KB	Share
CMB Appendix 4C - Quarterly
25/07/18	PRICE SENSITIVE	224.84KB	Share
CMB Response to ASX Price Query
23/07/18	PRICE SENSITIVE	985.56KB	Share
CMB US Patent Office to allow key patent for Progenza
10/07/18	PRICE SENSITIVE	104.26KB	Share
CMB Update on licensing Progenza in Japan
03/07/18	PRICE SENSITIVE	99.81KB	Share
CMB Grant of ASX Waiver
28/06/18	PRICE SENSITIVE	166.21KB	Share
CMB Appendix 4C - Quarterly
26/04/18	PRICE SENSITIVE	3.27MB	Share
CMB Appendix 3Y Change of Director's Interest Notice
20/04/18		226.04KB	Share
CMB Positive trial results of Progenza for knee OA published
07/03/18		1.5MB	Share
CMB Half-Year Results Presentation
20/02/18		682.6KB	Share
CMB Half-Year Results Announcement
20/02/18		117.2KB	Share
CMB Appendix 4D and Half-Year Report
20/02/18	PRICE SENSITIVE	1.04MB	Share
CMB European Medicines Agency grants Progenza ATMP status
14/02/18	PRICE SENSITIVE	106.87KB	Share
CMB Japanese Patent Office to grant patent for cancer vaccine
12/02/18	PRICE SENSITIVE	109.53KB	Share
CMB Regeneus Announces Successful Results in Acne Study
06/02/18	PRICE SENSITIVE	138.41KB	Share
CMB Appendix 4C - Quarterly
25/01/18	PRICE SENSITIVE	3.3MB	Share
CMB Regeneus appoints Japan-based non-executive director
11/12/17		796.11KB	Share
CMB Results of Annual General Meeting
02/11/17		843.63KB	Share
CMB CEO Presentation to 2017 Annual General Meeting
02/11/17	PRICE SENSITIVE	4.5MB	Share
CMB Chairman's Address to Shareholders
02/11/17		208.22KB	Share
CMB Presentation on Japan First Strategy at Ord Minnett
01/11/17		3.72MB	Share
CMB Appendix 4C - Quarterly
24/10/17	PRICE SENSITIVE	1.14MB	Share
CMB Notice of Annual General Meeting / Proxy Form
28/09/17		477.3KB	Share
CMB Sygenus shows longer lasting effect on pain than morphine
26/09/17	PRICE SENSITIVE	256.91KB	Share
CMB Date of AGM
06/09/17		370.74KB	Share
CMB Regeneus receives R&D tax incentive refund of $2.6m
29/08/17	PRICE SENSITIVE	181KB	Share
CMB Appendix 4E Revised
22/08/17	PRICE SENSITIVE	904.01KB	Share
CMB FY17 Results Presentation
22/08/17		5.12MB	Share
CMB FY17 Results Announcement
22/08/17		200.13KB	Share
CMB Appendix 4G and Corporate Governance Statement
22/08/17		8.99MB	Share
CMB Annual Report 2017
22/08/17		11.55MB	Share
CMB Appendix 4E
22/08/17	PRICE SENSITIVE	906.63KB	Share
CMB Appendix 4C - Quarterly
26/07/17	PRICE SENSITIVE	1.44MB	Share

REFRESH

First 2 3 4 5

(20min delay)
Last 38.0¢		Change 0.000(0.00%)		Mkt cap ! $4.533M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	2623	33.5¢

Sellers (Offers)

Price($)	Vol.	No.
37.5¢	40	1

View Market Depth

No.	Vol.	Price($)
1	2623	0.335
1	2000	0.330
2	2500	0.300
1	2000	0.290
1	3000	0.195

Price($)	Vol.	No.
0.375	40	1
0.380	67	1
0.395	13403	1
0.400	7905	1
0.000	0	0

Last trade - 10.02am 18/09/2024 (20 minute delay)

CMB (ASX) Chart

Day chart unavailable

CAMBIUM BIO LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available